ALK ‐positive lung cancer in a patient with recurrent brain metastases and meningeal dissemination who achieved long‐term survival of more than seven years with sequential treatment of five ALK ‐inhibitors: A case report-Reference-Cited by-同舟云学术

ALK ‐positive lung cancer in a patient with recurrent brain metastases and meningeal dissemination who achieved long‐term survival of more than seven years with sequential treatment of five ALK ‐inhibitors: A case report

Published:2021-05-03 Issue:11 Volume:12 Page:1761-1764
ISSN:1759-7706
Container-title:Thoracic Cancer
language:en
Short-container-title:Thorac Cancer

Author:

Yamamoto Keisuke¹,Toyokawa Gouji¹^ORCID,Kozuma Yuka¹,Shoji Fumihiro¹,Yamazaki Koji¹,Takeo Sadanori¹

Affiliation:

1. Department of Thoracic Surgery, Clinical Research Institute National Hospital Organization, Kyushu Medical Center Fukuoka Japan

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1759-7714.13962

Reference17 articles.

1. Large-cell anaplastic lymphoma-specific translocation (t[2;5] [p23;q35]) in Hodgkin's disease: indication of a common pathogenesis?

2. Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer

3. Non-solid oncogenes in solid tumors:EML4-ALKfusion genes in lung cancer

4. Genomic Alterations of Anaplastic Lymphoma Kinase May Sensitize Tumors to Anaplastic Lymphoma Kinase Inhibitors

5. CH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper Mutant

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anti-ALK autoantibodies in patients with ALK-positive Non-Small Cell Lung Cancer (NSCLC): A monocentric experience;The Journal of Liquid Biopsy;2024-12

2. New findings on the incidence and management of CNS adverse reactions in ALK-positive NSCLC with lorlatinib treatment;Discover Oncology;2024-09-13

3. Successful application of lorlatinib in a 23‐year‐old patient with anaplastic lymphoma kinase (ALK)‐positive lung cancer and multiple brain metastases;Cancer Reports;2024-01-11

4. Lorlatinib as a treatment for ALK-positive lung cancer;Future Oncology;2022-08

5. Update on Lorlatinib: Role in Reducing the Risk of Disease Progression in ALK-Positive NSCLC;Cancer Management and Research;2022-02